Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Scienture Holdings, Inc. completed an acquisition involving Superlatus, Inc. for 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the (closed 2023-07-31).
- Action
- acquisition
- Counterparty
- Superlatus, Inc.
- Consideration
- 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the
- Closing
- 2023-07-31
Exact text from the filing
the surviving entity in the Merger. Under the terms of the A&R Merger Agreement, at the closing of the Merger (the “Closing”), shareholders of Superlatus received in aggregate 136,441 shares of common stock of the Company, representing 19.9% of the total issued and outstanding common stock of the Company after the consummation of the Merger and 306,855 shares
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.87
Scienture Holdings, Inc. entered into Amended and Restated Agreement and Plan of Merger with Superlatus, Inc. valued at 136,441 shares of common stock ... and 306,855 shares of Company's Series B Preferred Stock (effective 2023-07-14).
- Action
- entry
- Agreement
- merger
- Counterparty
- Superlatus, Inc.
- Value
- 136,441 shares of common stock ... and 306,855 shares of Company's Series B Preferred Stock
- Effective
- 2023-07-14
Exact text from the filing
on July 14, 2023, TRxADE HEALTH, Inc., a Delaware corporation (the "Company" or "MEDS") entered into a certain Amended and Restated Agreement and Plan of Merger (the "A&R Merger Agreement") with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities ("Superlatus") and Foods Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company ("Merger Sub").
View on SEC.gov